Table 5.

Psychotropic medication prescribing practices after stratifying based on 25% use of long acting injectable

Treatment Characteristics	LAI <25%	LAI >/=25%	P value*
Antipsychotics
0 Antipsychotic, Median % (IQR)[^]	4.2(0.0–19.0)[26]	0.0(0.0–6.0)[26]	0.10
1 Antipsychotic	61.7(44.5–73.0)[26]	56.1(42.0–76.0)[26]	0.60
2 Antipsychotics	14.1(8.4–23.6)[20]	34.6(20.7–42.9)[20]	0.001
3 or more Antipsychotics	1.8(0.0–5.8)[20]	4.8(0.0–11.8)[20]	0.20
APP (>/= 2 Antipsychotics)a	22.0(15.2–35.0)[37]	35.7(18.5–46.0)[28]	0.04
First-generation antipsychotics	55.0(45.0–90.1)[34]	90.5(74.0–100)[24]	0.003
Second-generation antipsychotics	44.1(6.0–59.9)[26]	1.1(0.0–24.0)[19]	0.03
Clozapine	7.8(0.0–14.2)[26]	0.0(0.0–9.5)[16]	0.18
Long-acting injectable preparations	16.0(8.7–21.8)[37]	47.1(30.5–66.2)[28]	<0.0001
Comedications
Mood stabilizers b	19.9(14.2–22.7)[10]	6.5(4.0–11.1)[4]	0.03
Lithium b	4.3(1.9–10.0)[14]	4.7(3.0–7.2)[10]	0.95
Anticonvulsants b	7.3(4.0–10.7)[10]	1.0(0.0–5.7)[12]	0.007
Anxiolytics/hypnotics	32.0(15.7–40.0)[25]	33.1(15.0–39.0)[18]	0.94
Antidepressants	14.1(7.8–24.7)[27]	10.0(6.2–24.2)[17]	0.45
Anticholinergics	35.1(26.9–46.8)[27]	48.0(37.1–67.2)[17]	0.004
APP (>/= 2 Antipsychotics)
FGA + FGA	52.0(0.0–100)[23]	100(99.0–100)[15]	0.03
SGA + SGA	1.5(0.0–15.6)[21]	0.0(0.0–0.0)[15]	0.02
FGA + SGA	26.5(0.0–56.5)[24]	0.0(0.0–5.15)[16]	0.02
Long-acting injectable preparations	11.4(0.0–31.8)[10]	81.0(55.1–100)[16]	0.006

^*Mann-Whitney test.

^{^}Number of time points. IQR: Interquantile range (percentile 25–75). APP: Antipsychotic Polypharmacy. FGA: First-Generation Antipsychotic. SGA: Second-Generation Antipsychotic.

^aThe APP rate is not identical to the sum of patients taking 2 or >/=3 antipsychotics, as not all studies reporting on APP specified the exact number of antipsychotics prescribed;

^bAlthough overlapping conceptually, the terms “mood stabilizers”, “anticonvulsants” and “lithium” are taken directly from the publications.